PTIX — Stock Film
STOCK FILMSCENE 1/11PTIX · $0.22
Stock Expert AI presents
PTIX
Protagenic Therapeutics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Protagenic Therapeutics, Inc. A quick introduction.

On the stock market since 2021, it operates in the world of health and science. It has 1 employee. Now — the numbers.

on the stock market since 2021
1 employee
$390K market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
The sales picture, year by year.

Red columns mark years that ended in a loss.

$0
2021
$0
2022
$0
2023
$0
2024
$0
2025
In the vault right now:
$0
DEBT: $3.2M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
41
weak

Clearly below the class average.

FINANCIAL STRENGTH
46
weak

Clearly below the class average.

VALUATION
0
very weak

Clearly below the class average.

GROWTH
43
weak

Clearly below the class average.

PRICE MOMENTUM
10
very weak

Clearly below the class average.

WORTH WATCHING

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
Thin profit on each sale3/10
The stock has lost its spark3/10
WORTH WATCHING

Profit per Sale: The profit kept from each sale is thin.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Executives are buying their own stock

Over the last 12 months, company executives reported 2 buys and 1 sell. Management buying with its own money is usually read as a good sign.

2
THE BRIGHT SIDE · 2/2
Pays a steady dividend

It pays out $479,749,712 per share each year — regular cash for whoever holds the stock.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $5.2M against $0 in annual sales.

2
THE RISKS · 2/3
Trading under $1

The stock sits at $0.22. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

3
THE RISKS · 3/3
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, PTIX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: PTIX is a high-risk stock — not yet profitable, and its future rides on its product catching on.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film